Oncology
Refine search
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved German pharma major Bayer’s Hyrnuo (sevabertinib) to treat adults with advanced non-small cell lung cancer (NSCLC) with HER2 mutations, that has spread to other parts of the body or cannot be removed by surgery. 2 April 2026
Biotechnology
Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the European Union (EU) for platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 with a combined positive score of at lease one, and who have received one or two prior systemic treatment regimens. 2 April 2026
Biotechnology
Privately-held US cell therapy company Orca Bio announced that the US Food and Drug Administration (FDA) has extended the review timeline of its Biologics License Application (BLA) for Orca-T for the treatment of patients with hematologic malignancies. 2 April 2026
Biotechnology
Positive high-level results have been shared from the EMERALD-3 Phase III trial by AstraZeneca. 2 April 2026
Pharmaceutical
Precision oncology start-up Fore Biotherapeutics announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG). 2 April 2026
Pharmaceutical
US biotech ABK Biomedical has signed a long-term agreement with the University of Missouri Research Reactor (MURR), naming it the primary irradiation partner for Eye90 microspheres, a Y-90 radioembolization therapy targeting liver cancer. 1 April 2026
Biotechnology
Austrian biotech Proxygen, which is pioneering the discovery of molecular glue degraders and next-generation proximity-based therapeutics, today announced the appointment of Chiara Conti, as chief scientific officer (CSO). 31 March 2026
Biotechnology
Torqur, a subsidiary of the incubator Swiss Rockets that is advancing treatments for oncology and dermatology, has announced a collaboration with Lonza, the contract development and manufacturing organization (CDMO). 31 March 2026
Pharmaceutical
Last week’s significant research news included Pfizer and French partner Valneva releasing mixed data on their much-anticipated Phase III trial of Lyme disease vaccine candidate LB6V/VLA15. Also, Insmed announced top-line Phase IIIb data for its lung disease candidate Arikayce and regulatory filing plans. Among M&A news, Gilead Sciences announced a $2 billion+ deal to acquire Ouro Medicines and its TCE inhibitor gamgertamig, while Merck & Co revealed a takeover bid for Terns Pharmaceuticals and its leukemia candidate TERN-701. 29 March 2026
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its March 2026 meeting. 27 March 2026
Biotechnology
Johnson & Johnson today announced that the European Medicines Agency‘s (EMA) human medicines committee (CHMP) has granted approval for a Type II variation to the labelling for Darzalex (daratumumab) subcutaneous (SC) formulation. 27 March 2026
Pharmaceutical
Dutch specialty pharmaceutical company Norgine today announced that Swissmedic has granted marketing authorization for Pedmarqsi (sodium thiosulfate solution for infusion) indicated for the prevention of cisplatin induced ototoxicity (hearing loss) in patients aged 1 month to <18 years with localized, non-metastatic solid tumors. 26 March 2026
Pharmaceutical
More than two months before the US Food and Drug Administration (FDA) deadline date for a decision, the agency has approved Corcept Therapeutics’ Lifyorli (relacorilant) in ovarian cancer, sending shares in the firm 18% higher Wednesday. 26 March 2026
Pharmaceutical
Japan still matters to specialty drug makers for a simple reason: it has a large and fast-aging patient population, broad public insurance and one of the world’s biggest pharmaceutical markets. That combination keeps the country high on launch plans for companies with products in cancer, neurology, ophthalmology and other diseases linked to older age. 26 March 2026
Biotechnology
South Korean biotech Alteogen saw its shares rise 6.3% to 381,00 won, after it announced an exclusive license agreement with Biogen for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme technology. 26 March 2026
Pharmaceutical
Israel-based Purple Biotech today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech's next-generation tri-specific antibody platform leveraging advanced generative AI capabilities. 26 March 2026
Pharmaceutical
US precision medicine company Tempus AI has entered a strategic collaboration with Japanese drugmaker Daiichi Sankyo. 26 March 2026
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim today reported financial results, showing that group sales rose by 7.3% to 27.8 billion euros ($31.4 billion) for the full year, supported by both the Human Pharma and Animal Health business units. 25 March 2026
Pharmaceutical
US pharma giant Merck & Co and Terns Pharmaceuticals, a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck will acquire Terns. 25 March 2026
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for the additional indication of the combination therapy of anti-cancer agent / anti-CD20/CD3 humanized bispecific monoclonal antibody Lunsumio (mosunetuzumab) and anti-cancer agent/antimicrotubule-binding anti-CD79b monoclonal antibody Polivyintravenous (polatuzumab vedotin) for the treatment of relapsed or refractory large B-cell lymphoma. 25 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze